Page 266 - Basic _ Clinical Pharmacology ( PDFDrive )

252 SECTION III Cardiovascular-Renal Drugs

PREP AR A TIONS A V AIL ABLE

GENERIC NAME AVAILABLE AS GENERIC NAME AVAILABLE AS
SODIUM CHANNEL BLOCKERS ACTION POTENTIAL-PROLONGING AGENTS
Disopyramide Generic, Norpace, Amiodarone Generic, Cordarone
Norpace CR Dofetilide Tikosyn
Flecainide Generic, Tambocor Dronedarone Multaq
Lidocaine Generic, Xylocaine Ibutilide Generic, Corvert
Mexiletine Generic, Mexitil Sotalol Generic, Betapace
Procainamide Generic, Pronestyl, Procan-SR CALCIUM CHANNEL BLOCKERS
Propafenone Generic, Rythmol Diltiazem Generic, Cardizem
Quinidine sulfate Generic Verapamil Generic, Calan, Isoptin
(83% quinidine base) MISCELLANEOUS
Quinidine gluconate Generic Adenosine Generic, Adenocard
(62% quinidine base) Magnesium sulfate Generic
Quinidine polygalacturonate Cardioquin DRUGS THAT ACT ON CHLORIDE CHANNELS
(60% quinidine base)
BETA BLOCKERS LABELED FOR USE AS ANTIARRHYTHMICS Ivacaftor (labeled for Kalydeco
use in cystic fibrosis)
Acebutolol Generic, Sectral
Crofelemer (labeled for Fulyzaq
Esmolol Generic, Brevibloc use in diarrhea induced
Propranolol Generic, Inderal by anti-HIV drugs)

REFERENCES Hondeghem LM: Relative contributions of TRIaD and QT to proarrhythmia.
J Cardiovasc Electrophysiol 2007;18:655.
Antzelevitch C, Burashnikov A: Overview of basic mechanisms of cardiac arrhythmia.
Card Electrophysiol Clin 2011;3:23. Kolettis TM: Coronary artery disease and ventricular arrhythmias: Pathophysiol-
ogy and treatment. Curr Opin Pharm 2013;13:210.
Bezzina CR, Lahrouchi N, Priori SG: Genetics of sudden cardiac death. Circ Res
2015;116:1919. Li A, Behr ER: Advances in the management of atrial fibrillation. Clin Med
2012;12:544.
Burashnikov A, Antzelevitch C: Role of late sodium channel block in the manage- Marrus SB, Nerbonne JM: Mechanisms linking short- and long-term electrical
ment of atrial fibrillation. Cardiovas Drugs Ther 2013;27:79. remodeling in the heart … Is it a stretch? Channels 2008;2:117.
Chinitz JS et al: Rate or rhythm control for atrial fibrillation: Update and contro- McPhail GL, Clancy JP: Ivacaftor: The first therapy acting on the primary cause
versies. Am J Med 2012;125:1049. of cystic fibrosis. Drugs Today 2013;49:253.
Cho HC, Marban E: Biological therapies for cardiac arrhythmias: Can genes and Mohler PJ, Gramolini AO, Bennett V: Ankyrins. J Cell Biol 2002;115:1565.
cells replace drugs and devices? Circ Res 2010;106:674.
Das MK, Zipes DP: Antiarrhythmic and nonantiarrhythmic drugs for sudden Monfredi O, Maltsev VA, Lakatta EG: Modern concepts concerning the origin of
the heartbeat. Physiology 2013;28:74.
cardiac death prevention. J Cardiovasc Pharmacol 2010;55:438.
Duan D: Phenomics of cardiac chloride channels: The systemic study of chloride Morady F: Catheter ablation of supraventricular arrhythmias: State of the art.
J Cardiovasc Electrophysiol 2004;15:124.
channel function in the heart. J Physiol 2009;587:2163.
Echt DS et al, for the CAST Investigators: Mortality and morbidity in patients Roubille F, Tardif J-C: New therapeutic targets in cardiology, heart failure and
arrhythmia: HCN channels. Circulation 2013;127:1986.
receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppres-
sion Trial. N Engl J Med 1991;324:781. Starmer FC, Grant AO, Strauss HC: Mechanisms of use-dependent block of sodium
channels in excitable membranes by local anesthetics. Biophys J 1984;46:15.
El-Sherif N, Boutjdir M: Role of pharmacotherapy in cardiac ion channelopathies.
Pharmacol Ther 2015;155:132. Tradtrantip L, Namkung W, Verkman AS: Crofelemer, an antisecretory antidiar-
rheal proanthocyandin oligomer extracted from Croton lechleri, targets two
El-Sherif N, Turitto G: Electrolyte disorders and arrhythmogenesis. Cardiol J distinct intestinal chloride channels. Mol Pharmacol 2010;77:69.
2011;18:233. Veerakul G, Nademanec K: Brugada syndrome: Two decades of progress. Circ
Fedida D: Vernakalant (RSD1235): A novel, atrial-selective antifibrillatory agent. J 2012;76:2713.
Expert Opin Investig Drugs 2007;16:519. Vizzardi E et al: A focus on antiarrhythmic properties of ranolazine. J Cardiovasc
Fuster V et al: ACC/AHA/ESC Guidelines for the management of patients with Pharm Ther 2012;17:353.
atrial fibrillation. Circulation 2006;114:700. Wehrens XHT, Lehnart SE, Marks AR: Ryanodine receptor-targeted anti-arrhythmic
George AL: Molecular and genetic basis of sudden cardiac death. J Clin Invest therapy. NY Acad Sci 2005;1047:366.
2013;123:75. Wolbrette D et al: Dronedarone for the treatment of atrial fibrillation and atrial
Grant AO: Cardiac ion channels. Circ Arrhythmia Electrophysiol 2009;2:185. flutter: Approval and efficacy. Vasc Health Risk Manag 2010;6:517.